October 13, 2009
Assuming most girls are vaccinated against the virus that causes cervical cancer, encouraging boys to get the vaccine is not cost-effective, concludes a recent report.
"There may be better uses and other health interventions that would increase health gains in the population," said Harvard School of Public Health researcher Jane Kim. She and colleague Sue Goldie describe their study in the British Medical Journal.
Merck & Co.'s human papillomavirus vaccine Gardasil has been shown to be effective in protecting boys and men against the virus, and the Food and Drug Administration is considering whether to approve the vaccine for males ages 9-26. It is approved already for use in girls and young women.
10.08.2009; Julie Steenhuysen
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.